Importance The incidence of acute lymphoblastic leukemia (ALL) and lymphoblastic
lymphoma (LBL) in adolescent and young adult (AYA) patients (age range, 15-39 years) in …

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring
at an annual incidence rate of approximately 1.1–2.1 per 100,000 person-years globally …

Compared to younger and older age groups, the incidence of acute lymphoblastic leukemia
(ALL) and lymphoblastic lymphoma (LBL) has increased more in the adolescent and young …

For young adults with acute lymphoblastic leukemia, pediatric‐based regimens are likely to
provide the following when compared to hyper‐CVAD regimens: better disease control, less …

Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic
leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true …

Advances in our understanding of mechanisms of leukemogenesis and driver mutations in
acute lymphoblastic leukemia (ALL) lead to a more precise and informative sub …

Four categories of important factors improving outcome of young adults and older
adolescents with acute lymphoblastic leukemia (ALL) are biologic type, clinical trials …

Abstract Background The outcomes of Pediatric acute lymphoblastic leukemia (ALL) have
improved dramatically whereas outcomes for ALL amongst adolescents and young adults …

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the
clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, the …

Background Hyper-CVAD is an established regimen for adult ALL that was developed at the
MD Anderson Cancer Center (MDACC). However, results can vary across different …